Professor Karsten Suhre and Dr. Christian Gieger of Helmholtz Zentrum München, together with colleagues from Wellcome Trust Sanger Institute in the UK and King’s College London under the lead of Nicole Soranzo, conducted this research to gain in-depth insight into the etiology of disease. In the study, the scientists present the most comprehensive evaluation of genetic variance in human metabolism so far, combining genome-wide association studies * (GWAS) with metabolomics*. Over 250 metabolytes were analyzed from 60 disease-relevant metabolic pathways.
“The advantage of our study design,” Suhre and Gieger said, “is that we studied genetic variance in its biological context – and thus identified previously unknown risk loci.” By combining genetics and metabolomics, a method which already showed promising results in two previous studies, the scientists were able to evaluate the biological effect of the identified genetic risk loci. In stand-alone GWAS this is not possible.
Every individual is unique – a closer look at the individual’s metabolites could enable a better evaluation of the risks for developing complex common diseases in the future. “We have made considerable advances in understanding complex diseases such as type 2 diabetes mellitus,” the two scientists said. “The findings of the study will lead to new approaches for pharmaceutical research.”
The aim of Helmholtz Zentrum München is to better understand the etiology of complex common diseases and to derive new targets for diagnosis, therapy and prevention.